The FDA has approved an abbreviated new drug application for Alembic Pharmaceuticals’ tobramycin ophthalmic solution USP 0.3%, according to a press release.
The generic drug, which is equivalent to Tobrex ophthalmic solution 0.3% (Novartis), is indicated to treat external infections of the eye and its adnexa caused by susceptible bacteria.
The solution currently has an estimated market size of $9.6 million, the release said.
Uncategorized